1 |
1 |
use |
13 |
that may decrease psa levels e . g . saw palmetto |
5 |
2 |
4 |
no use |
2 |
that may decrease psa levels within 4 weeks prior to enrollment |
2 |
3 |
6 |
user |
1 |
that may have hormonal anti prostate cancer activity and / or are known to decrease psa levels e . g . saw palmetto within 4 weeks of study drug administration day 1 |
1 |
4 |
2 |
|
NA |
that may have hormonal anti prostate cancer activity and / or are known to decrease psa levels e . g . saw palmetto or systemic corticosteroids within 6 months of enrollment |
1 |
5 |
3 |
|
NA |
|
1 |
6 |
5 |
|
NA |
that may decrease psa levels i . e . saw palmetto no washout period required |
1 |
7 |
7 |
|
NA |
that may decrease psa levels i . e . saw palmetto or systemic corticosteroid greater than the equivalent of 10 mg of prednisone per day during the 4 weeks prior to screening or plans to initiate treatment with the above during the entire duration of the study |
1 |
8 |
8 |
|
NA |
that may have hormonal anti prostate cancer activity and / or are known to decrease psa levels e . g . saw palmetto or systemic corticosteroids greater than the equivalent of replacement steroids or > = equivalent of 10 mg of prednisone per day within 4 weeks of enrollment day 1 visit |
1 |
9 |
9 |
|
NA |
that may have hormonal anti prostate cancer activity and / or are known to decrease psa levels e . g . saw palmetto or systemic corticosteroids greater than the equivalent of 10 mg of prednisone per day within 2 weeks of enrollment |
1 |
10 |
10 |
|
NA |
that may have hormonal anti prostate cancer activity and / or are known to decrease psa values e . g . saw palmetto or systemic corticosteroids for prostate cancer within 4 weeks of day 29 visit start of enzalutamide and adt |
1 |
11 |
11 |
|
NA |
that may have hormonal anti prostate cancer activity and / or are known to decrease psa levels e . g . saw palmetto or systemic corticosteroids greater than the equivalent of 10 mg of prednisone per day within 4 weeks of enrollment |
1 |